Financials data is unavailable for this security.
View more
Year on year Valeo Pharma Inc had net income fall 8.01% from a loss of 25.75m to a larger loss of 27.81m despite revenues that grew 94.31% from 27.75m to 53.91m over the same period.
Gross margin | 16.51% |
---|---|
Net profit margin | -60.18% |
Operating margin | -37.50% |
Return on assets | -82.64% |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in CADView more
In 2023, cash reserves at Valeo Pharma Inc fell by 15.00m. Cash Flow from Financing totalled 6.19m or 11.48% of revenues. In addition the company used 15.70m for operations while cash used for investing totalled 5.55m.
Cash flow per share | -0.3128 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.6388 |
---|---|
Tangible book value per share | -0.7469 |
More ▼
Balance sheet in CADView more
Current ratio | 0.2726 |
---|---|
Quick ratio | 0.202 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 9.94 |
More ▼